Dr. Reddy's Laboratories Limited
NSE: DRREDDY BSE: DRREDDY
NSE
1,320.90
30.30 (2.35%)
Prev Close
1290.6
Open Price
1295.1
Volume
2,158,463
Today Low / High
1295 / 1322.9
52 WK Low / High
1020 / 1421.49
Range
1,255 - 1,387
BSE
1,320.50
30.60 (2.37%)
Prev Close
1289.9
Open Price
1301.8
Volume
74,396
Today Low / High
1296.4 / 1322.4
52 WK Low / High
1025.9 / 1420.2
Range
1,254 - 1,387
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1320.9 (target range: 1,255 - 1,387), reflecting a change of 30.3 (2.34775%). On the BSE, it is listed at 1320.5 (target range: 1,254 - 1,387), showing a change of 30.6 (2.37228%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
06 Jun
1,295.10
1.99%
05 Jun
1,264.20
2.09%
04 Jun
1,248.30
0.29%
03 Jun
1,250.00
-0.14%
02 Jun
1,251.00
-0.26%
30 May
1,248.20
0.24%
29 May
1,245.40
0.22%
28 May
1,247.80
-0.42%
27 May
1,243.90
-0.06%
26 May
1,229.90
0.89%
23 May
1,228.00
0.17%
22 May
1,224.70
-0.20%
21 May
1,225.10
-0.03%
20 May
1,222.00
0.18%
19 May
1,228.30
-0.76%
16 May
1,238.90
-0.66%
15 May
1,214.00
1.84%
14 May
1,213.30
0.55%
13 May
1,196.00
0.93%
12 May
1,155.90
3.43%
09 May
1,142.50
1.17%
Dr. Reddy's Laboratories Limited Graph
Dr. Reddy's Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Dr. Reddy's Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,320.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,320.50 | 1,333.71 | 1,200.33 - 1,467.08 |
| 1,346.91 | 1,077.53 - 1,616.29 | ||
| 1,360.12 | 952.08 - 1,768.15 | ||
| Bearish Scenario | 1,320.50 | 1,307.30 | 1,176.57 - 1,438.02 |
| 1,294.09 | 1,035.27 - 1,552.91 | ||
| 1,280.89 | 896.62 - 1,665.15 |
Overview of Dr. Reddy's Laboratories Limited
ISIN
INE089A01023
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
2,217,821
Market Cap
1,100,458,988,118
Last Dividend
8
Official Website
IPO Date
1996-01-01
DCF Diff
-1,065.69
DCF
2,282
Financial Ratios Every Investor Needs
Stock Dividend of DRREDDY
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-10 | July 10, 25 | 8 | 8 | 2025-07-10 | 2025-08-23 | |
| 2024-07-16 | July 16, 24 | 8 | 40 | 2024-07-16 | 2024-08-28 | |
| 2023-07-11 | July 11, 23 | 40 | 200 | 2023-07-11 | 2023-08-26 | |
| 2022-07-11 | July 11, 22 | 30 | 150 | 2022-07-12 | 2022-08-28 | |
| 2021-07-09 | July 09, 21 | 5 | 25 | 2021-07-12 | 2021-08-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 32,553.50 Cr | 13,510.70 Cr | 19,042.80 Cr | 0.5850 | 2,738.00 Cr | 0.00 Cr | 7,184.30 Cr | 5,654.40 Cr | 67.88 | 9,161.10 Cr | 0.1737 |
| 2024-03-31 | 27,916.40 Cr | 11,555.70 Cr | 16,360.70 Cr | 0.5861 | 2,287.30 Cr | 0.00 Cr | 6,772.90 Cr | 5,568.40 Cr | 334.41 | 8,827.50 Cr | 0.1995 |
| 2023-03-31 | 24,587.90 Cr | 7,657.70 Cr | 16,930.20 Cr | 0.6886 | 1,938.10 Cr | 4,646.60 Cr | 5,714.40 Cr | 4,506.70 Cr | 271.43 | 7,406.10 Cr | 0.1833 |
| 2022-03-31 | 21,439.10 Cr | 10,055.10 Cr | 11,384.00 Cr | 0.5310 | 1,748.20 Cr | 0.00 Cr | 2,947.60 Cr | 2,356.80 Cr | 142.08 | 4,774.30 Cr | 0.1099 |
| 2021-03-31 | 18,972.20 Cr | 8,664.50 Cr | 10,307.70 Cr | 0.5433 | 1,654.10 Cr | 0.00 Cr | 2,619.10 Cr | 1,723.80 Cr | 103.94 | 4,570.60 Cr | 0.0909 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,465.40 Cr | 49,298.90 Cr | 15,582.30 Cr | 33,338.8000 Cr | 4,676.60 Cr | 3,211.20 Cr | 7,108.50 Cr | 9,776.10 Cr | 0.00 Cr | 0.00 Cr | 1,520.20 Cr | 13,039.2000 Cr |
| 2024-03-31 | 710.70 Cr | 38,751.80 Cr | 10,696.80 Cr | 28,055.0000 Cr | 2,002.00 Cr | 1,291.30 Cr | 6,355.20 Cr | 7,688.60 Cr | 143.50 Cr | 119.30 Cr | 525.50 Cr | 9,603.9000 Cr |
| 2023-03-31 | 577.90 Cr | 32,285.10 Cr | 8,999.00 Cr | 23,286.1000 Cr | 1,347.20 Cr | 769.30 Cr | 4,867.00 Cr | 5,654.20 Cr | 198.10 Cr | 155.50 Cr | 608.90 Cr | 8,572.1000 Cr |
| 2022-03-31 | 1,485.20 Cr | 29,665.40 Cr | 10,612.70 Cr | 19,052.7000 Cr | 3,384.50 Cr | 1,899.30 Cr | 5,088.40 Cr | 6,216.90 Cr | 257.60 Cr | 159.70 Cr | 798.60 Cr | 9,784.2000 Cr |
| 2021-03-31 | 1,482.90 Cr | 26,549.10 Cr | 9,051.00 Cr | 17,498.1000 Cr | 3,030.80 Cr | 1,547.90 Cr | 4,541.20 Cr | 5,711.10 Cr | 203.30 Cr | 153.10 Cr | 833.30 Cr | 8,147.2000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,642.8000 Cr | -5,102.1000 Cr | 1,185.5000 Cr | 1,892.4000 Cr | 748.6000 Cr | 1,459.3000 Cr | -2,750.4000 Cr | 5,654.4000 Cr | -129.4000 Cr | -666.2000 Cr | -1,275.3000 Cr |
| 2024-03-31 | 4,543.3000 Cr | -4,028.3000 Cr | -376.3000 Cr | 1,799.8000 Cr | 132.8000 Cr | 710.7000 Cr | -2,743.5000 Cr | 5,568.4000 Cr | 434.6000 Cr | -664.8000 Cr | -1,844.5000 Cr |
| 2023-03-31 | 5,887.3000 Cr | -4,137.1000 Cr | -2,686.1000 Cr | 4,000.9000 Cr | -907.3000 Cr | 577.9000 Cr | -1,886.4000 Cr | 6,048.5000 Cr | -1,938.2000 Cr | -497.9000 Cr | -265.4000 Cr |
| 2022-03-31 | 2,810.8000 Cr | -2,638.7000 Cr | -242.2000 Cr | 905.9000 Cr | 3.2000 Cr | 1,485.2000 Cr | -1,904.9000 Cr | 2,356.8000 Cr | 273.5000 Cr | -414.6000 Cr | -532.8000 Cr |
| 2021-03-31 | 3,570.3000 Cr | -2,266.0000 Cr | -29.8000 Cr | 2,314.2000 Cr | 1,285.8000 Cr | 1,482.0000 Cr | -1,256.1000 Cr | 1,914.9000 Cr | -69.7000 Cr | -414.7000 Cr | -988.1000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8,506.00 Cr | 3,779.70 Cr | 4,726.30 Cr | 0.5556 | 1,764.70 Cr | 1,593.90 Cr | 19.13 | 2,141.80 Cr | 0.1874 |
| 2024-12-31 | 8,358.60 Cr | 3,453.40 Cr | 4,905.20 Cr | 0.5868 | 1,872.00 Cr | 1,413.30 Cr | 16.96 | 2,423.70 Cr | 0.1691 |
| 2024-09-30 | 8,016.20 Cr | 3,458.10 Cr | 4,558.10 Cr | 0.5686 | 1,755.10 Cr | 1,255.30 Cr | 15.04 | 2,383.80 Cr | 0.1566 |
| 2024-06-30 | 7,672.70 Cr | 3,250.10 Cr | 4,422.60 Cr | 0.5764 | 1,754.20 Cr | 1,392.00 Cr | 83.58 | 2,175.70 Cr | 0.1814 |
| 2024-03-31 | 7,083.00 Cr | 2,934.70 Cr | 4,148.30 Cr | 0.5857 | 1,413.00 Cr | 1,307.00 Cr | 78.49 | 2,028.60 Cr | 0.1845 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,465.40 Cr | 4,325.40 Cr | 5,790.80 Cr | 9,042.00 Cr | 7,108.50 Cr | 25,011.20 Cr | 9,776.10 Cr | 49,298.90 Cr | 15,582.30 Cr |
| 2024-12-31 | 1,228.90 Cr | 4,689.00 Cr | 5,917.90 Cr | 11,149.40 Cr | 7,163.00 Cr | 25,301.60 Cr | 9,305.30 Cr | 48,105.90 Cr | 15,949.40 Cr |
| 2024-09-30 | 1,133.00 Cr | 5,174.40 Cr | 6,307.40 Cr | 9,190.30 Cr | 7,203.90 Cr | 24,812.80 Cr | 8,669.30 Cr | 46,595.50 Cr | 15,667.20 Cr |
| 2024-06-30 | 491.30 Cr | 8,971.30 Cr | 9,462.60 Cr | 8,108.80 Cr | 6,856.80 Cr | 26,918.80 Cr | 8,034.30 Cr | 41,529.70 Cr | 12,067.00 Cr |
| 2024-03-31 | 710.70 Cr | 7,436.30 Cr | 8,147.00 Cr | 8,029.80 Cr | 6,355.20 Cr | 24,804.90 Cr | 7,688.60 Cr | 38,751.80 Cr | 10,696.80 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,593.90 Cr | 2,199.60 Cr | -624.40 Cr | -1,442.60 Cr | 156.10 Cr | 1,459.30 Cr | 1,303.20 Cr | -766.20 Cr | 1,433.40 Cr |
| 2024-12-31 | 1,403.80 Cr | 662.00 Cr | -545.80 Cr | 59.00 Cr | 174.70 Cr | 1,303.20 Cr | 1,128.50 Cr | -881.90 Cr | -219.90 Cr |
| 2024-09-30 | 1,255.30 Cr | 931.60 Cr | -1,284.90 Cr | 1,003.10 Cr | 637.20 Cr | 1,128.50 Cr | 491.30 Cr | -790.90 Cr | 140.70 Cr |
| 2024-06-30 | 1,392.00 Cr | 819.80 Cr | -2,069.40 Cr | 1,028.50 Cr | -219.40 Cr | 491.30 Cr | 710.70 Cr | -642.40 Cr | 177.40 Cr |
| 2024-03-31 | 1,307.00 Cr | 1,129.00 Cr | -1,177.80 Cr | 14.00 Cr | -42.80 Cr | 710.70 Cr | 753.50 Cr | -628.30 Cr | 500.70 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2024-10-28 | October 28, 24 | 5:1 |
| 2006-08-28 | August 28, 06 | 2:1 |
| 2001-10-10 | October 10, 01 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Executive Vice President, Global Head of Global Manufacturing & Member of Management Council
Mr. Sanjay Sharma B.Tech.
Gender: male
Year Born: 1968
Chief Executive Officer of API & Services & Member of Management Council
Mr. Deepak Sapra M.B.A.
Gender: male
Year Born: 1975
EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
Ms. Archana Bhaskar B.Sc., M.B.A.
Gender: female
Year Born: 1967
Co-Chairman, MD & Member of Management Council
Mr. Gunupati Venkateswara Prasad B.E.
Gender: male
Year Born: 1960
Chief Executive Officer of European Generics & Member of Management Council
Mr. Patrick Aghanian B.A., M.B.A.
Gender: male
Year Born: 1965
Global Head of Quality and Pharmacovigilance & Member of the Management Council
Mr. Krishna K. Venkatesh B.Pharma M.S.
Gender: male
Year Born: 1973
Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council
Mr. Venkata Ramana Motupalli M.B.A.
Gender: male
Year Born: 1969
Chief Financial Officer & Member of the Management Council
Mr. Mannam Venkatanarasimham
Gender: male
Year Born:
Chairman of the Board & Member of the Management Council
Mr. Kallam Satish Reddy B.Tech., M.S.
Gender: male
Year Born: 1967
Chief Executive Officer & Member of the Management Council
Mr. Erez Israeli M.B.A.
Gender: male
Year Born: 1968
FAQs about Dr. Reddy's Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Erez Israeli M.B.A..
What is the current market price of the stock?
The current price is ₹1,320.90.
What is the 52-week price range?
The range is ₹1020-1421.49.
What is the market capitalization of the company?
The market capitalization is ₹110,045.90 crores.
What is the dividend yield?
The dividend yield is 0.61%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 3.89.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Dr. Reddy's Laboratories Limited (ISIN: INE089A01023) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹110,045.90 crores and an average daily volume of 2,217,821 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹8.